Amcenestrant in combination with CDK4/6 inhibitor palbociclib demonstrates synergistic anti-tumor activity in ER plus endocrine-resistant breast cancer xenograft models

被引：1
作者：
Shomali, Maysoun
Guo, Zhuyan
Cheng, Jane
Sullivan, Amy
El-Ahmad, Youssef
Sun, Fangxian
Sidhu, Sukhvinder
Lee, Joon Sang
Cai, Hui
Pollard, Jack
Debussche, Laurent
Soria, Chris
Bouaboula, Monsif
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P4-02-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-02-08
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Synergistic anti-tumor activity of CDK4/6 inhibitor combined with paclitaxel in NSCLC cells harboring mutant KRAS
    Zhang, Xiang-Hua
    Shin, Jung-Young
    Kim, Jeong-Oh
    Oh, Ji-Eun
    Chae, Hiun Suk
    Kang, Jin-Hyoung
    CANCER RESEARCH, 2012, 72
  • [22] Glucose Metabolic Reprogramming of ER+ Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
    Lorito, Nicla
    Bacci, Marina
    Smiriglia, Alfredo
    Mannelli, Michele
    Parri, Matteo
    Comito, Giuseppina
    Ippolito, Luigi
    Giannoni, Elisa
    Bonechi, Martina
    Benelli, Matteo
    Migliaccio, Ilenia
    Malorni, Luca
    Chiarugi, Paola
    Morandi, Andrea
    CELLS, 2020, 9 (03)
  • [23] Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells
    Kishino, Emi
    Ogata, Ryohei
    Saitoh, Wataru
    Koike, Yoshikazu
    Ohta, Yusuke
    Kanomata, Naoki
    Kurebayashi, Junichi
    BREAST CANCER, 2020, 27 (03) : 415 - 425
  • [24] Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells
    Emi Kishino
    Ryohei Ogata
    Wataru Saitoh
    Yoshikazu Koike
    Yusuke Ohta
    Naoki Kanomata
    Junichi Kurebayashi
    Breast Cancer, 2020, 27 : 415 - 425
  • [25] AP-1 as a potential mediator of resistance to the cyclin-dependent kinase (CDK) 4/6-inhibitor palbociclib in ER-positive endocrine-resistant breast cancer
    De Angelis, Carmine
    Nardone, Agostina
    Cataldo, Maria Letizia
    Veeraraghavan, Jamunarani
    Fu, Xiaoyong
    Giuliano, Mario
    Malorni, Luca
    Jeselsohn, Rinath
    Osborne, Kent C.
    Schiff, Rachel
    CANCER RESEARCH, 2018, 78 (04)
  • [26] Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
    Alves, Carla L.
    Ehmsen, Sidse
    Terp, Mikkel G.
    Portman, Neil
    Tuttolomondo, Martina
    Gammelgaard, Odd L.
    Hundebol, Monique F.
    Kaminska, Kamila
    Johansen, Lene E.
    Bak, Martin
    Honeth, Gabriella
    Bosch, Ana
    Lim, Elgene
    Ditzel, Henrik J.
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [27] G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
    Andreano, Kaitlyn J.
    Wardell, Suzanne E.
    Baker, Jennifer G.
    Desautels, Taylor K.
    Baldi, Robert
    Chao, Christina A.
    Heetderks, Kendall A.
    Bae, Yeeun
    Xiong, Rui
    Tonetti, Debra A.
    Gutgesell, Lauren M.
    Zhao, Jiong
    Sorrentino, Jessica A.
    Thompson, Delita A.
    Bisi, John E.
    Strum, Jay C.
    Thatcher, Gregory R. J.
    Norris, John D.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (03) : 635 - 646
  • [28] G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
    Kaitlyn J. Andreano
    Suzanne E. Wardell
    Jennifer G. Baker
    Taylor K. Desautels
    Robert Baldi
    Christina A. Chao
    Kendall A. Heetderks
    Yeeun Bae
    Rui Xiong
    Debra A. Tonetti
    Lauren M. Gutgesell
    Jiong Zhao
    Jessica A. Sorrentino
    Delita A. Thompson
    John E. Bisi
    Jay C. Strum
    Gregory R. J. Thatcher
    John D. Norris
    Breast Cancer Research and Treatment, 2020, 180 : 635 - 646
  • [29] Longitudinal, multimodal profiling of metastatic ER plus breast cancer on CDK4/6 inhibitor therapy
    Creason, Allison L.
    Egger, Julian
    Watson, Cameron
    Sivagnanam, Shamilene
    Lin, Jia-Ren
    Chin, Koei
    Sorger, Peter K.
    Coussens, Lisa M.
    Mitri, Zahi I.
    Gray, Joe W.
    Mills, Gordon B.
    Goecks, Jeremy
    CANCER RESEARCH, 2023, 83 (07)
  • [30] Patient derived tumor xenograft study with CDK4/6 inhibitor plus AKT inhibitor for management of metastatic castrate resistant prostate cancer.
    Kase, Adam McLain
    Tan, Winston
    Gleba, Justyna
    Miller, James
    Meurice, Nathalie
    Petit, Joachim
    Copland, John A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345